Recruiting PHASE1 INTERVENTIONAL 2-arm NCT07030790

A Phase I Clinical Study of a Single Dose of KLA480

A Single-center, Randomized, Double-blind, Placebo-Controlled, Dose Escalation, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of a Single Subcutaneous Injection of KLA480 Injection in Healthy Chinese Participants

Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Conditions Healthy Participants

Interventions KLA480 injection Placebo

Updated 1 time since 2025 Last updated: Jun 12, 2025 Started: May 17, 2025 Primary completion: Dec 31, 2026 Completion: Mar 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07030790, this PHASE1 trial focuses on Healthy Participants and remains actively recruiting participants. Sponsored by Sichuan Kelun Pharmaceutical Research Institute Co., Ltd., it has been updated 1 time since 2025, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

1 version recorded

Recruiting — PHASE1 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Data source: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China